5,N,N-TMT

In today's world, 5,N,N-TMT has become a topic of great relevance and debate. Since its origin, 5,N,N-TMT has impacted people's lives in various ways, generating conflicting opinions and divergent positions. Its influence has transcended borders and has marked a before and after in the history of humanity. Over time, 5,N,N-TMT has been the object of study, analysis and reflection, and its importance has not stopped growing. In this article, we will explore the different facets of 5,N,N-TMT, analyzing its impact on current society and its projection in the future.

5,N,N-TMT
Identifiers
  • (2-(5-methyl-1H-indol-3-yl)-1-methyl-ethyl)dimethylamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.164.424 Edit this at Wikidata
Chemical and physical data
FormulaC13H18N2
Molar mass202.301 g·mol−1
3D model (JSmol)
  • c1c(ccc2c1c(c2)CCN(C)C)C
  • InChI=1S/C13H18N2/c1-10-4-5-13-12(8-10)11(9-14-13)6-7-15(2)3/h4-5,8-9,14H,6-7H2,1-3H3 checkY
  • Key:NCGJLYBZSJSCIC-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

5,N,N-trimethyltryptamine (5,N,N-TMT; 5-TMT) is a tryptamine derivative that is a psychedelic drug. It was first made in 1958 by Edwin H. P. Young.[1] In animal experiments it was found to be in between DMT and 5-MeO-DMT in potency[2][3] which would suggest an active dosage for humans in the 20–60 mg range. Human psychoactivity for this compound has been claimed in reports on websites such as Erowid but has not been independently confirmed.[medical citation needed]

United States

5,N,N-TMT is not scheduled at the federal level in the United States,[4][5] but it could be considered an analog of 5-MeO-DMT, in which case, sales or possession intended for human consumption could be prosecuted under the Federal Analog Act.

See also

References

  1. ^ Young EH (1958). "704. The synthesis of 5-hydroxytryptamine (serotonin) and related tryptamines". Journal of the Chemical Society (Resumed): 3493–6. doi:10.1039/JR9580003493.
  2. ^ Glennon RA, Gessner PK (April 1979). "Serotonin receptor binding affinities of tryptamine analogues". Journal of Medicinal Chemistry. 22 (4): 428–32. doi:10.1021/jm00190a014. PMID 430481.
  3. ^ Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
  4. ^ "§ 1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
  5. ^ "§ 1308.11 Schedule I." e-CFR. 2022-02-17. Archived from the original on 2022-02-10.


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.